MOLECULAR DISSECTION OF ANGIOGENESIS THROUGH GENE DISCOV

描述：（改编自研究者摘要）本快速通道阶段 I-阶段II STTR应用的目标是开发一种新的相关 研究血管生成（血管生长）的实验系统 这是在合作研究机构开发的。作者 将使用高通量基因发现（全长）的技术平台 cDNA克隆），其已经在OriGene Technologies，Inc.（OTI）。在 在第一阶段，OTI提出生成表达序列标签 (EST的）500个基因，这些基因在连续的 在他们的实验系统中检测到的血管形成阶段。 这些EST克隆将为阶段中的大规模cDNA分离奠定基础。 二.提议。具体而言，合作研究机构将 负责分离足够量的来源于 在通过生长信号激活之前和之后的体内动物模型，和 用于对回收的RNA进行严格的质量控制。基于 已经成功进行的可行性测试的结果， OTI将使用源RNA识别，扩增和测序约500个 EST代表基因被抑制或激活， 内皮细胞开始在模型系统中形成血管。 拟议商业应用：不可用

DESCRIPTION: (Adapted from the investigator's abstract) This Fast-Track Phase I-Phase II STTR application is targeted at exploiting a novel and relevant experimental system for the study of angiogenesis (the growth of blood vessels) that has been developed at the partnering research institution. The authors will use a technology platform for high-throughput gene discovery (full-length cDNA cloning) that has been established at OriGene Technologies, Inc. (OTI). In this Phase I component, OTI proposes to generate expressed sequence tags (EST's) for 500 genes which are either turned on or turned off at successive stages of blood vessel formation as detected in their experimental system. These EST clones will set the stage for large-scale cDNA isolation in the Phase II proposal. Specifically, the partnering research institution will be responsible for isolating sufficient quantities of source RNA derived from the in vivo animal model, both before and after activation by a growth signal, and for performing stringent quality controls on the recovered RNA. Based upon the results of feasibility tests that have already been successfully carried out, OTI will use the source RNA's to identify, amplify, and sequence about 500 EST's which represent genes that are either repressed or activated as endothelial cells begin to form blood vessels in the model system. PROPOSED COMMERCIAL APPLICTION: NOT AVAILABLE